Bayer holds below the 40 euro mark, shares trade softer on Xetra

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 14:24.

Bayer (DE000BAY0017) starts Thursday trading with its shares changing hands below the 40 euro threshold on Xetra, placing the stock among the weaker names in the DAX pharmaceutics segment as the broader Euro Stoxx 50 opens in positive territory according to finanzen.at.Finanzen.at quote and market overview

What the chart picture shows

On Xetra the Bayer shares recently quote around 39.46 euros, with finanzen.at reporting a decline of roughly 1 percent versus the previous close and a course time of 25 June 2026 at 09:30.Finanzen.at intraday data That leaves the stock trading clearly below the psychological 40 euro mark, a level that for many retail traders serves as a short-term orientation line.

Tradegate data show comparable prints, with the order book listing a last price of 39.56 euros and a daily change of around -0.83 percent in the morning session, highlighting a slightly softer tone across off-exchange trading compared with the prior day.Tradegate BSX order book for Bayer Bid and ask levels at 39.55 and 39.67 euros point to a narrow spread, suggesting orderly trading despite the mild pressure on the shares.

Analyst sentiment and recent news

Beyond the intraday moves, analyst sentiment remains cautious. MarketScreener records that in mid-June the research boutique Sadif Investment Analytics downgraded Bayer to Sell while lifting the price target, reflecting concerns over litigation and balance sheet strength even as valuation arguments evolve.MarketScreener Bayer overview with analyst notes Around the same time, AlphaValue/Baader Europe adjusted its stance to Add and also raised its target, underscoring that houses differ on how much risk is already priced into the stock.

Recent corporate headlines show Bayer active on the portfolio and partnership side. The company completed the acquisition of Perfuse Therapeutics, adding cardiovascular-focused innovation to its pipeline, and announced a collaboration with Iambic Therapeutics to advance drug discovery using artificial intelligence, according to the MarketScreener news feed that aggregates Reuters and company releases.MarketScreener news stream on Bayer These steps fit into Bayer’s broader effort to strengthen its pharma division amid ongoing challenges in crop science and legacy litigation.

What the company sells

Bayer generates revenue across three major divisions: Pharmaceuticals, Consumer Health and Crop Science. In the over-the-counter segment one of its best-known global brands is Aspirin, a pain reliever and blood-thinning medication that is sold in tablet form through pharmacies and retailers in many markets and remains a key legacy franchise for the group.

Where the stock trades today

The Bayer shares (DE000BAY0017) trade on Xetra at around 39.46 euros as of 2026-06-25, 09:30, based on finanzen.at data, placing the company in the DAX with a market capitalization in the mid tens of billions of euros.

Disclaimer: This article is for information purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to engage in any securities transaction. All data are based on sources cited and are subject to change.